Catalog #CP098
RecombiMAb anti-mouse ACKR4 (CCR11) (LALA-PG)
Clone
A4Mab-3-CP098
Reactivities
Mouse
Isotype
Mouse IgG2a (LALA-PG), κ
(switched from Rat Ig2b, κ)
(switched from Rat Ig2b, κ)
You may also be interested in:
Product Description
The A4Mab-3-CP098 monoclonal antibody is a recombinant, chimeric version of the original A4Mab-3 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2b, κ to mouse IgG2a, κ for use in murine models. Additionally, A4Mab-3-CP098 contains LALA-PG mutations in the heavy chain Fc fragment rendering it unable to bind endogenous murine Fcγ receptors or C1q to induce antibody-dependent, cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The LALA-PG variant has demonstrated significantly reduced effector function, C1q binding and C3 fixation compared to other common silencing mutations such as the LALA and DANG variants while retaining favorable biophysical and manufacturing properties. Species-matched chimeric antibodies demonstrate reduced immunogenicity and formation of anti-drug antibodies (ADAs) compared to xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The A4Mab-3 monoclonal antibody reacts with mouse atypical chemokine receptor 4 (ACKR4), also known as CCR11, CCRL1, CCX CKR, PPR1, and CCBP2. ACKR4 is expressed on T cells, stromal cells, and a subset of lymphatic endothelial cells within the skin, spleen, and gut. ACKR4 is a seven-transmembrane domain-containing protein that belongs to the atypical chemokine receptors (ACKRs) family. Due to their function, ACKRs are considered chemokine decoy receptors, internalizing receptors (interceptors), or chemokine-scavenging receptors. They mediate β-arrestin-dependent internalization of chemokines, followed by lysosomal degradation of the receptor-ligand complex. ACKR4 plays a key role in regulating cell migration by reducing the availability of inflammatory chemokines, specifically CCL19, CCL22, and CCL25, thereby limiting migratory responses mediated by CCR7, CCR6, CCR4, and CCR9. ACKR4 negatively regulates CXCR3-induced chemotaxis and facilitates the homing of CC7+ dendritic cells through scavenging and shaping CCL19 and CCL21 gradients in lymph nodes. ACKR4 is also involved in the regulation of thymic T-cell development and suppression of spontaneous autoimmunity. Loss of ACKR4 in colorectal cancer in mice is reported to impair DC migration to tumor-draining lymph nodes, which leads to a reduced number of tumor-specific T cells and resistance to immune checkpoint blockade therapy.
The A4Mab-3 monoclonal antibody reacts with mouse atypical chemokine receptor 4 (ACKR4), also known as CCR11, CCRL1, CCX CKR, PPR1, and CCBP2. ACKR4 is expressed on T cells, stromal cells, and a subset of lymphatic endothelial cells within the skin, spleen, and gut. ACKR4 is a seven-transmembrane domain-containing protein that belongs to the atypical chemokine receptors (ACKRs) family. Due to their function, ACKRs are considered chemokine decoy receptors, internalizing receptors (interceptors), or chemokine-scavenging receptors. They mediate β-arrestin-dependent internalization of chemokines, followed by lysosomal degradation of the receptor-ligand complex. ACKR4 plays a key role in regulating cell migration by reducing the availability of inflammatory chemokines, specifically CCL19, CCL22, and CCL25, thereby limiting migratory responses mediated by CCR7, CCR6, CCR4, and CCR9. ACKR4 negatively regulates CXCR3-induced chemotaxis and facilitates the homing of CC7+ dendritic cells through scavenging and shaping CCL19 and CCL21 gradients in lymph nodes. ACKR4 is also involved in the regulation of thymic T-cell development and suppression of spontaneous autoimmunity. Loss of ACKR4 in colorectal cancer in mice is reported to impair DC migration to tumor-draining lymph nodes, which leads to a reduced number of tumor-specific T cells and resistance to immune checkpoint blockade therapy.
Specifications
| Isotype | Mouse IgG2a (LALA-PG), κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | LALA-PG |
| Immunogen | A synthetic peptide corresponding to the N-terminal extracellular region of mACKR4 (amino acids 1-19) |
| Reported Applications |
Flow cytometry ELISA For details on in vivo applications please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |